Nexalin Technology has received U.S. patent for its non-invasive Deep Intracranial Frequency Stimulation device for Alzheimer's and dementia. The device is part of a market projected to reach over $28 billion by 2030.
Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching the placebo.
XPeng CEO tests Tesla's full self-driving software in the US, invites comparisons with XPeng's XNGP, amid company's new product launches and market developments.